NEW YORK (GenomeWeb News) — Gene Logic today said it will help Merck Serono, a division of German drug maker Merck, identify alternative development paths for “several” undisclosed drug candidates.
All of the candidates were discontinued or “de-prioritized” in clinical trials for reasons other than safety, according to Gene Logic.
Under the deal, Gene Logic stands to pocket milestones and royalties “similar to those paid for development-stage in-licensing deals,” though discounted for an undisclosed amount because Merck Serono originally discovered the compounds.
The deal also gives Gene Logic the option to receive an exclusive license to any candidate for which the company identifies a “new potential therapeutic use” that Merck Serono chooses not to develop. In that case, Merck Serono would stand to receive milestones and royalties, Gene Logic said.
Though the companies did not disclose the indications for which these candidates would be considered, Gene Logic in a statement called Merck Serono a “world leader” in reproductive health with “strong market positions in several other therapeutic areas.”